Angel Pharma, a Jiaxing- Los Angeles company, was approved to start China clinical trials of a small molecule ITK inhibitor in patients with relapsed/refractory T-cell lymphomas. CPI-818, the first ITK inhibitor in clinical development, is designed to selectively inhibit ITK (interleukin-2-inducible T-cell kinase) without affecting related kinases such as RLK and BTK. Corvus Pharma discovered the drug. One year ago, Corvus formed Angel as a China JV with $106 million in original capital and China rights to three of its assets, including CPI-818.  More details.... Stock Symbol: (NSDQ: CRVS) Share this with colleagues: // //